Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
Disc Medicine completed a Type A meeting with the FDA regarding the Complete Response Letter for its bitopertin NDA in erythropoietic protoporphyria. The company and the FDA agreed that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response and potentially support traditional approval.
Key figures
- Drug Name
- bitopertin
- Phase Of Trial
- Phase 3
- Apollo data expected
- Q4 2026
- Fda decision expected
- mid-2027
- Crl response submission
- end of 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.